Chelsea Michaud, DO
Allergy & Immunology · Portland, MENPI 1073878468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,445, more than ten times the $24 reported in 2019.
Across 319 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- Sanofi$950
- CSL Behring$546
- GSK$464
- Takeda Pharmaceuticals U.S.A., Inc.$435
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,60897%
- Education$2023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 65 | $1,237 |
| AstraZeneca | 51 | $1,215 |
| Sanofi | 44 | $950 |
| CSL Behring | 24 | $546 |
| GSK | 26 | $464 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $435 |
| Novartis | 23 | $378 |
| Pharming Healthcare, Inc. | 10 | $242 |
| Amgen(2 entities) | 10 | $213 |
| Biocryst US Sales Co., LLC | 9 | $202 |
| Blueprint Medicines Corporation | 3 | $118 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $109 |
| Pfizer | 6 | $98 |
| Grifols USA, LLC | 4 | $83 |
| Phadia US Inc. | 1 | $83 |
| Sanofi-aventis U.S. LLC | 2 | $76 |
| X4 Pharmaceuticals, Inc. | 2 | $65 |
| Ionis Pharmaceuticals, Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Kaleo, Inc. | 3 | $40 |
| Tersera Therapeutics LLC | 1 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Incyte Corporation | 1 | $25 |
| USWM, LLC | 1 | $18 |
| Merck | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| AbbVie | 1 | $12 |
How this compares
Too few allergy & immunology providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 76 | $285,938 |
| TezspireTezepelumab-Ekko | 29 | $128,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $59,141 |
| XolairOmalizumab | 20 | $53,843 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $38,170 |
| Arnuity ElliptaFluticasone Furoate | 65 | $17,776 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $12,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,574 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,879 |
| DuleraMometasone/Formoterol | 17 | $8,491 |
| AlvescoCiclesonide | 20 | $6,027 |
| Fluticasone Propionate HfaFluticasone Propionate | 21 | $5,920 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,583 |
| Epinephrine | 20 | $3,788 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $3,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $1,215 | $150,87475 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $464 | $115,087219 claims |
| MerckDulera | $17 | $8,49117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Maineon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Portland
- Jonathan MusmandPortland$239K
- Ivan CardonaPortland$9K
- Andrew ParkerPortland$6K
- Russell BehmerPortland$1K
- Rung-Chi LiBangor$17K
- Paul ShaperoBangor$13K
- Calvin FuhrmannKennebunk$7K
- Scott DyerAugusta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.